Early clinical trial highlights cancer vaccines as potential affordable, safe and effective breast cancer treatment
The upcoming clinical trials KEYNOTE‑756 (NCT03725059) and KEYNOTE‑B49 (NCT04895358) will evaluate the efficacy of pembrolizumab as a neoadjuvant checkpoint inhibitor in patients with hormone‑receptor‑positive, HER2‑negative and triple‑negative breast cancer, respectively.
Dr. Hope S. Rugo emphasized key directions for breast cancer research, including optimizing therapy intensity, refining immunotherapy use, advancing antibody‑drug conjugates, preventing brain metastases, and addressing global disparities in care.
The results of these trials could broaden the indications for immunotherapy in breast cancer, offering improved treatment options for subgroups that historically have limited benefit from checkpoint blockade.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC